Solid Biosciences (SLDB) Operating Expenses (2017 - 2026)

Solid Biosciences (SLDB) has 10 years of Operating Expenses data on file, last reported at $57.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 43.08% year-over-year to $57.3 million; the trailing twelve-month figure through Mar 2026 stood at $196.5 million (up 37.46% YoY), and the FY2025 full-year result was $179.2 million, up 38.14% from the prior year.
• Operating Expenses rose to $57.3 million in Q1 2026, from $49.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $57.3 million in Q1 2026 to a low of $21.1 million in Q3 2022.
• A 5-year average of $34.4 million and a median of $32.0 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 35.59% in 2023 and jumped 79.19% in 2024, its largest moves.
• Tracing SLDB's Operating Expenses over 5 years: stood at $34.6 million in 2022, then slumped by 35.59% to $22.3 million in 2023, then jumped by 79.19% to $39.9 million in 2024, then rose by 23.83% to $49.4 million in 2025, then increased by 16.0% to $57.3 million in 2026.
• Business Quant data shows SLDB's Operating Expenses at $57.3 million in Q1 2026, $49.4 million in Q4 2025, and $48.1 million in Q3 2025.